Cost-effectiveness of tenecteplase versus alteplase for stroke thrombolysis evaluation trial in the ambulance.
Lan GaoMark ParsonsLeonid ChurilovHenry ZhaoBruce Cv CampbellBernard YanPeter MitchellSkye CooteFrancesca LangenbergKaren SmithDavid AndersonMichael StephensonStephen M DavisGeoffrey DonnanDamien EastonAndrew BivardPublished in: European stroke journal (2023)
Treatment of ischaemic stroke patients with tenecteplase appeared to be cost-effective and improve QALYs in the MSU setting based on Phase II data. The reduced total cost from tenecteplase was driven by savings from acute hospitalisation and reduce need for nursing home care.
Keyphrases
- phase ii
- clinical trial
- open label
- phase iii
- acute ischemic stroke
- liver failure
- atrial fibrillation
- pulmonary embolism
- placebo controlled
- double blind
- study protocol
- healthcare
- respiratory failure
- electronic health record
- randomized controlled trial
- machine learning
- drug induced
- big data
- acute respiratory distress syndrome
- cerebral ischemia
- deep learning